Compass Financial Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.27K Sell
49
-496
-91% -$25.4K ﹤0.01% 1434
2026
Q2
$28.5K Buy
+545
New +$24.3K ﹤0.01% 812

Other funds holding BBC

Compass Financial Management's BBC Position: Q3 2026 in Review

Compass Financial Management reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 91% in Q3 2026, selling an estimated $25.4K and leaving 49 shares worth $2.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1434.

Compass Financial Management first reported a position in BBC in Q2 2026 and has held it in 2 quarters since. The position peaked at $28.5K in Q2 2026. 13 funds tracked by Wall St. Rank hold BBC as of Q3 2026.

  • Compass Financial Management held 49 shares of Virtus Biotech Clinical Trials ETF worth $2.27K as of Q3 2026.
  • Compass Financial Management sold 496 Virtus Biotech Clinical Trials ETF shares in Q3 2026, an estimated $25.4K.
  • Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Compass Financial Management's portfolio in Q3 2026, its #1434 holding.
  • Compass Financial Management first reported a position in Virtus Biotech Clinical Trials ETF in Q2 2026 and has held it in 2 quarters since.
  • Compass Financial Management's Virtus Biotech Clinical Trials ETF position peaked at $28.5K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q3 2026.

Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.